1. Introduction

Affordability regulation of biotechnology medicines in Australia concerns the legal and regulatory mechanisms used to make expensive biological medicines accessible to patients while balancing pharmaceutical innovation, public expenditure, patient safety, and the commercial interests of manufacturers.

Biotechnology medicines, or biologics, are medicines produced using living cells or biological processes. They include monoclonal antibodies, recombinant proteins, certain vaccines, blood products, and many advanced therapies.

Examples include biologic medicines used to treat cancer, rheumatoid arthritis, inflammatory bowel disease, and rare genetic disorders.

The Australian framework does not rely on a single statute governing medicine affordability. Instead, it combines:

Pharmaceutical Benefits Scheme (PBS): government subsidisation of eligible medicines.

Pharmaceutical pricing and reimbursement: assessment of clinical benefit and cost-effectiveness.

Therapeutic Goods Administration (TGA): quality, safety and efficacy regulation.

Biosimilar regulation: pathways supporting competition between comparable biological medicines.

Price disclosure and expenditure controls: mechanisms intended to manage medicine expenditure.

Judicial review and administrative law: legal scrutiny of decisions made by public authorities.

A central legal distinction is that TGA approval does not automatically entitle a medicine to PBS reimbursement. A medicine can be approved for sale but remain expensive or unavailable through government subsidy.

2. Statutory framework governing affordability

A. National Health Act 1953 (Cth)

The National Health Act 1953 is the principal legislative foundation for the PBS.

Important provisions include:

Under section 101(3A), PBAC must consider the effectiveness and cost of a proposed therapy, including comparisons with alternative treatments. Section 101(3B) imposes an additional requirement where a therapy is substantially more costly than alternatives: PBAC must be satisfied that it offers a significant improvement in efficacy or reduction in toxicity for some patients before recommending it.

These provisions are important for expensive biotechnology medicines because they connect public subsidy to comparative clinical value and expenditure.

Federal Register of Legislation

+1

B. Therapeutic Goods Act 1989 (Cth)

The Therapeutic Goods Act 1989 establishes the legal framework for regulating therapeutic goods, including medicines assessed by the Therapeutic Goods Administration (TGA).

The TGA assesses matters such as quality, safety and efficacy. A biosimilar must demonstrate an appropriate degree of similarity to its reference biological medicine through comprehensive comparability evidence.

However, regulatory approval and affordability are different legal questions:

TGA registration determines whether a medicine can lawfully be supplied subject to applicable requirements.

PBS listing determines whether and on what conditions the Commonwealth subsidises the medicine.

PBS pricing arrangements determine the applicable government reimbursement and price framework.

Consequently, a biologic can be registered but not PBS-subsidised, or subsidised only for specific diseases and eligible patients.

Therapeutic Goods Administration (TGA)

+1

C. Pharmaceutical Benefits Advisory Committee

The Pharmaceutical Benefits Advisory Committee is an independent expert committee that advises the government on whether medicines should be listed on the PBS.

Its assessment can consider:

Comparative clinical effectiveness.

Safety and adverse effects.

Cost-effectiveness compared with existing treatments.

The severity of the condition and unmet medical need.

The financial consequences of listing.

Appropriate restrictions, eligible patient groups and treatment conditions.

PBAC recommendations are not themselves the final act of listing. Pricing negotiations, administrative processes and government consideration follow a positive recommendation.

PBAC Outcomes

+1

This system seeks to avoid two opposing outcomes: subsidising a very expensive treatment without sufficient evidence of additional value, and denying patients access to a clinically important medicine merely because its initial price is high.

3. Main mechanisms for making biotechnology medicines affordable

1. PBS subsidies

Eligible patients pay the applicable patient contribution rather than the full subsidised medicine cost. The Commonwealth pays the relevant subsidy under the PBS framework. Listing may be restricted by diagnosis, previous treatment, clinical response or specialist prescribing requirements.

2. Biosimilar competition

Biosimilars are highly similar biological medicines compared with an approved reference product. Entry by competing products can create opportunities for lower prices and improved affordability, although the actual effect depends on market entry, reimbursement arrangements and clinical uptake.

3. Cost-effectiveness assessment

PBAC evaluates the additional health benefits of a proposed treatment against its additional costs. A manufacturer may need to revise its proposed price or provide further evidence before a listing can proceed.

4. Price disclosure and price reductions

Statutory price-disclosure arrangements can require manufacturers to report relevant supply-price information. For covered products, the resulting calculations may reduce the approved ex-manufacturer price.

The legislative basis for PBS pricing and price disclosure appears in the National Health Act 1953. The TGA explains the potential affordability benefits of biosimilar entry, while PBS guidance describes the role of cost-effectiveness in reimbursement decisions.

Federal Register of Legislation

+2

Example: an expensive cancer biologic

Suppose a manufacturer develops a new monoclonal antibody for a cancer and proposes a high price.

The process may unfold as follows:

The TGA assesses the evidence supporting registration.

The manufacturer applies for PBS listing.

PBAC assesses the treatment's clinical benefits and cost-effectiveness.

If the proposed price does not support a favourable reimbursement assessment, the manufacturer may need to submit further evidence or negotiate a lower price.

If listed, the medicine may be subsidised only for defined cancer types, disease stages or patient groups.

The legal objective is not to impose a universal low price on every biologic. It is to establish conditions under which public funds can support treatment while maintaining reasonable access and fiscal sustainability.

4. Important case laws on medicine affordability and pharmaceutical competition

A key point for legal research is that Australian courts have addressed PBS pricing, patent protection, generic entry and reimbursement-related losses. These decisions are relevant to biotechnology affordability, although they do not all concern biologic medicines directly.

Case 1: Commonwealth of Australia v Sanofi [2024] HCA 47

High Court of Australia · 11 December 2024

Facts

Sanofi held a patent relating to clopidogrel, a medicine used to reduce the risk of blood clots. It obtained an interlocutory injunction in 2007 preventing Apotex from supplying a competing generic product. Sanofi gave an undertaking to compensate persons adversely affected by the injunction.

The patent was subsequently held invalid on appeal. The Commonwealth argued that preventing generic entry had delayed PBS price reductions and caused it to incur additional subsidy expenditure.

Legal issue

Could the Commonwealth recover its alleged additional PBS costs under the undertaking given in support of the injunction?

Decision

The High Court dismissed the Commonwealth's appeal. The Court upheld the lower courts' factual findings that the Commonwealth had not established the necessary causal connection for most of its claimed loss. The decision also addressed the evidential burden involved in proving loss under an undertaking as to damages.

High Court of Australia

+1

Legal principles

A party claiming compensation must establish the relevant causal connection between the injunction and the loss claimed.

A hypothetical claim that a generic medicine would have entered the PBS market requires adequate evidence.

Pharmaceutical competition can affect government subsidy expenditure, but a claimed saving is not automatically recoverable as legal damages.

Relevance to biotechnology affordability

This case illustrates how patent litigation can affect the timing of competing medicines entering the market. The same economic concern can arise when patents or related disputes delay competing biosimilars.

However, the case concerned a conventional pharmaceutical product, not a biosimilar. Its importance is the broader principle connecting competition, market entry and PBS expenditure.

Official judgment: Read the High Court judgment and case materials.

Case 2: Commonwealth of Australia v Sanofi [2023] FCAFC 97

Full Court of the Federal Court of Australia · 26 June 2023

This was an earlier stage of the same dispute.

Facts and issue

The Commonwealth sought compensation for alleged losses arising from delayed generic clopidogrel entry. It argued that generic competition would have triggered PBS price reductions and reduced government expenditure.

Decision

The Full Court dismissed the Commonwealth's appeal, leaving intact the primary judge's findings concerning the evidentiary deficiencies and the claimed losses.

High Court of Australia

+1

Legal significance

The case highlights the difference between:

showing that competition generally tends to reduce prices;

proving that a particular competitor would actually have entered the PBS market; and

proving that the resulting loss falls within the scope of a particular legal undertaking.

For biotechnology medicines, these distinctions matter when a manufacturer alleges that a patent dispute, regulatory delay or competing-product exclusion has caused a financial loss.

Official case record: High Court case record and procedural history.

Case 3: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50

High Court of Australia · 4 December 2013

Facts

The dispute concerned patents relating to pharmaceutical substances and their therapeutic uses. It raised questions about the patentability of methods of medical treatment and the scope of pharmaceutical patent infringement.

Decision and principle

The High Court considered the application of Australian patent law to inventions involving therapeutic uses of pharmaceutical substances. The case is important for understanding the legal boundaries of pharmaceutical patents and competing-product supply.

High Court of Australia

Relevance to biotechnology medicines

Biologic medicines frequently involve complex patent portfolios covering active substances, formulations, manufacturing processes and therapeutic uses. Patent validity and infringement disputes can influence when a biosimilar manufacturer can lawfully enter the market.

Nevertheless, patentability does not itself determine whether a medicine should receive PBS subsidy. Patent law and reimbursement law perform different functions.

Official judgment: Read the High Court decision.

Case 4: Commonwealth v Sanofi [2015] FCAFC 172

Full Court of the Federal Court of Australia · 7 December 2015

Facts

This litigation considered pharmaceutical patent injunctions, generic suppliers' attempts to obtain regulatory registration and PBS listing, and the Commonwealth's ability to recover losses under undertakings given to courts.

Legal significance

The dispute addressed the relationship between patent-related injunctions, statutory provisions governing generic medicines, and claims for compensation based on alleged losses to the PBS.

CaseChat AU

Relevance

For biotechnology products, similar issues may arise where patent litigation delays a competing biosimilar. The precise legal outcome depends on the patent rights, statutory provisions, evidence of market entry and terms of any undertaking.

This is a useful supporting authority for studying how patent enforcement may interact with public medicine expenditure, rather than a direct ruling on biologic pricing.

5. Biosimilars and affordability regulation

A biosimilar is not simply a conventional generic medicine. Because biological products are produced using living systems and may have complex molecular structures, manufacturers must demonstrate an appropriate degree of similarity to the reference product.

The TGA's framework requires comprehensive comparability evidence covering relevant quality, biological, immunological, safety and efficacy characteristics.

Therapeutic Goods Administration (TGA)

+1

Legal and economic significance

How biosimilar competition can reduce costs

Patent protection and exclusivity periods

Regulatory approval of a biosimilar

PBS listing and applicable substitution arrangements

Potentially lower prices and reduced public expenditure

This is a general pathway, not an automatic sequence. Patent disputes, reimbursement negotiations, supply constraints and clinical restrictions can affect the outcome.

Biosimilar substitution

Australia permits substitution between certain biosimilar and reference brands under applicable PBS arrangements. PBS guidance explains that pharmacists can substitute appropriately flagged brands in permitted circumstances, taking account of the prescription and relevant restrictions.

pbs.gov.au

This is significant because competition requires more than regulatory approval: the product must also be available to patients through practical prescribing, dispensing and reimbursement arrangements.

Substitution must not be treated as universally permissible for every biologic, every patient or every stage of treatment.

6. Price disclosure and statutory price reduction

Under the National Health Act's price-disclosure framework, responsible persons for covered pharmaceutical brands must provide prescribed information concerning supplies, prices and related matters.

The legislation provides for weighted-average disclosed prices to be determined and, in specified circumstances, for approved ex-manufacturer prices to be reduced. Failure to comply can also attract statutory consequences.

Federal Register of Legislation

+1

Application to biotechnology medicines

The relevant question is whether the particular medicine or brand is covered by the applicable provisions and pricing arrangements.

It would be inaccurate to assume that every biologic is automatically subject to every price-disclosure mechanism. The statutory definitions, listing status and applicable exemptions must be examined.

The objective of these provisions is to make government reimbursement more responsive to actual market prices, particularly where competition and commercial discounts affect the cost of supplying medicines.

7. Special access and patient affordability

Not every medicine is accessible through an ordinary PBS listing. The Australian Government also uses special arrangements under section 100 of the National Health Act for particular medicines and patient groups.

These arrangements can cover selected treatments for chronic conditions, chemotherapy, growth hormone treatment, and other specified circumstances. Availability depends on the applicable arrangements and eligibility requirements.

Health.gov.au

+1

For a patient who cannot afford an expensive biotechnology medicine, the relevant legal and administrative questions include:

Is the medicine registered by the TGA?

Is the required indication subsidised under the PBS?

Does the patient satisfy the relevant eligibility and clinical criteria?

Is a special access or supply arrangement available?

Are there other clinically appropriate treatments or assistance pathways?

A medicine's high cost alone does not create an automatic legal entitlement to government reimbursement. Equally, the absence of an ordinary PBS listing does not necessarily mean that every other access pathway is closed.

8. Critical legal analysis

Affordability regulation involves several competing considerations.

The central challenge is to ensure that pricing decisions are evidence-based and legally authorised, while avoiding unnecessary barriers to competition and access.

A further distinction is necessary: a medicine may be cost-effective but still create a substantial total budget impact if many patients require treatment. Conversely, a high-priced medicine for a small population may have a large individual cost but a different overall budget impact. Both considerations can matter in reimbursement decisions.

9. Conclusion

Australian affordability regulation of biotechnology medicines is a combination of public subsidy, clinical and economic assessment, price regulation, biosimilar competition, patent law and administrative decision-making.

The principal authorities discussed here establish several important propositions:

PBS listing is distinct from TGA registration.

Cost-effectiveness is a statutory consideration in recommending medicines for PBS listing.

Competition can reduce medicine prices, but the legal consequences of delayed entry depend on evidence and applicable law.

Biosimilar substitution and price disclosure operate under defined legal conditions, rather than as universal rules.

There is no automatic entitlement to PBS funding simply because a biotechnology medicine is clinically valuable or expensive.

The most directly relevant judicial authority for the relationship between pharmaceutical competition and PBS affordability is Commonwealth of Australia v Sanofi [2024] HCA 47. It should be read alongside the National Health Act 1953, current PBS listing requirements and TGA biosimilar guidance.

Academic note: The cases above principally concern conventional pharmaceuticals and generic competition, not a comprehensive body of decisions specifically about biologic affordability. They provide relevant principles by analogy; they should not be described as direct judicial rulings on every aspect of biotechnology-medicine pricing.